Payment overview · 2025
General Payments
$1,462.84
94 reported records · 19 companies
Healthcare provider profile · identity verified
Joshua A Clark, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · FORT SMITH, AR · NPI 1265632368
Verified facts
What the public records show
CMS Open Payments records show Joshua A Clark, M.D. received $1,462.84 in general payments during 2025 across 94 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $316.12 | 21.6% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $301.37 | 20.6% | 21 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $245.07 | 16.8% | 18 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $145.79 | 10.0% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $142.95 | 9.8% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $85.37 | 5.8% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.82 | 2.2% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.11 | 1.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $17.57 | 1.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.13 | 1.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.10 | 1.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.56 | 1.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.43 | 1.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.17 | 1.1% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $15.65 | 1.1% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $15.62 | 1.1% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $15.10 | 1.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.23 | 1.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $13.68 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,457.84 | 93 |
| Education | $5.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $262.35 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $195.56 | 14 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $195.56 | 14 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $163.83 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $153.54 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $147.83 | 14 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $129.57 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $127.32 | 11 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $125.78 | 12 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $114.35 | 10 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $77.87 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $54.45 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $49.51 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $39.19 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.76 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.82 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $30.76 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $19.52 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.11 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.56 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.78 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $15.62 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $15.10 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $13.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 76 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 79 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 82 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 167 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 63 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
31 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
79 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
27 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
63 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
82 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
167 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
76 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 907 | 277 |
| Amlodipine Besylate | Amlodipine Besylate | 522 | 161 |
| Levothyroxine Sodium | Levothyroxine Sodium | 433 | 113 |
| Lisinopril | Lisinopril | 377 | 121 |
| Losartan Potassium | Losartan Potassium | 337 | 98 |
| Omeprazole | Omeprazole | 325 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 291 | 81 |
| Potassium Chloride | Potassium Chloride | 269 | 71 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 262 | 81 |
| Hydrochlorothiazide | Hydrochlorothiazide | 243 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 231 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 224 | 59 |
| Gabapentin | Gabapentin | 204 | 62 |
| Metformin Hcl Er | Metformin Hcl | 199 | 59 |
| Carvedilol | Carvedilol | 195 | 55 |
| Duloxetine Hcl | Duloxetine Hcl | 178 | 48 |
| Furosemide | Furosemide | 176 | 55 |
| Meloxicam | Meloxicam | 176 | 66 |
| Ozempic | Semaglutide | 167 | 35 |
| Valsartan | Valsartan | 165 | 52 |
| Trazodone Hcl | Trazodone Hcl | 149 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 146 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 145 | 45 |
| Metformin Hcl | Metformin Hcl | 140 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 137 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 130 | 35 |
| Allopurinol | Allopurinol | 129 | 34 |
| Buspirone Hcl | Buspirone Hcl | 126 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 124 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 122 | 40 |
| Sertraline Hcl | Sertraline Hcl | 121 | 37 |
| Tramadol Hcl | Tramadol Hcl | 119 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 100 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 99 | 25 |
| Mirtazapine | Mirtazapine | 94 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 92 | 47 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 92 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 90 | 29 |
| Simvastatin | Simvastatin | 86 | 23 |
| Clonazepam | Clonazepam | 85 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 84 | 19 |
| Jardiance | Empagliflozin | 82 | 20 |
| Farxiga | Dapagliflozin Propanediol | 79 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 77 | 17 |
| Eliquis | Apixaban | 76 | 17 |
| Ezetimibe | Ezetimibe | 75 | 25 |
| Pregabalin | Pregabalin | 74 | 16 |
| Lorazepam | Lorazepam | 73 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 73 | 13 |
| Glipizide Er | Glipizide | 70 | 19 |
| Ondansetron Odt | Ondansetron | 70 | 32 |
| Glipizide | Glipizide | 69 | 16 |
| Celecoxib | Celecoxib | 68 | 29 |
| Montelukast Sodium | Montelukast Sodium | 67 | 18 |
| Donepezil Hcl | Donepezil Hcl | 65 | 17 |
| Clonidine Hcl | Clonidine Hcl | 63 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 63 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 63 | 13 |
| Memantine Hcl | Memantine Hcl | 61 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 56 | 46 |
| Alendronate Sodium | Alendronate Sodium | 55 | 21 |
| Mounjaro | Tirzepatide | 55 | suppressed |
| Alprazolam | Alprazolam | 52 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 52 | 14 |
| Prednisone | Prednisone | 47 | 36 |
| Eszopiclone | Eszopiclone | 45 | suppressed |
| Novolog Flexpen | Insulin Aspart | 45 | 16 |
| Promethazine Hcl | Promethazine Hcl | 44 | suppressed |
| Estradiol | Estradiol | 42 | 13 |
| Propranolol Hcl | Propranolol Hcl | 41 | suppressed |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Famotidine | Famotidine | 39 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Bupropion Xl | Bupropion Hcl | 35 | 11 |
| Finasteride | Finasteride | 35 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | 11 |
| Cefdinir | Cefdinir | 33 | 29 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | 12 |
| Spironolactone | Spironolactone | 32 | suppressed |
| Topiramate | Topiramate | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 27 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | 11 |
| Tradjenta | Linagliptin | 31 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Glimepiride | Glimepiride | 28 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 27 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Ketoconazole | Ketoconazole | 23 | 15 |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Repatha Sureclick | Evolocumab | 23 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 21 | 11 |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Sulindac | Sulindac | 21 | suppressed |
| Dutasteride | Dutasteride | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 15 |
| Linzess | Linaclotide | 18 | suppressed |
| Nystatin | Nystatin | 18 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Minoxidil | Minoxidil | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 12 |
| Naproxen | Naproxen | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Dayvigo | Lemborexant | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,462.84 · 94 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AUSTEDO XR, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE, GEMTESA, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, QULIPTA, QUTENZA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, WATCHMAN Access System, Wegovy, XIFAXAN, YUPELRI, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error